The numbers, charted.
Reported weight loss at peak dose
Plasma half-life
HbA1c reduction (T2D cohorts)
GI side-effect frequency
"Which one for…"
Maximum weight loss research
Triple-agonism wins on raw weight outcomes. Retatrutide leads the bench at 24% mean weight reduction. Tirzepatide is the runner-up with more long-term data.
Best evidence base
Semaglutide has the most published data: SUSTAIN, STEP, SELECT — five major program trees. The conservative pick when weight loss isn't the top priority.
Best tolerability profile
Tirzepatide adds GIP agonism to GLP-1, which clinically appears to dampen GI side effects relative to semaglutide at matched weight-loss levels. The pragmatic pick for sensitive patients.
Tendon & soft-tissue recovery research
BPC-157 has the broader mechanism portfolio. TB-500 has a more clinical-trial-driven base (TIME trial in cardiac repair). Patients often run both.
Visceral fat & body comp research
Tesamorelin is a GHRH analog with FDA-approved data for visceral adipose tissue reduction — the pick when the question is fat distribution, not raw weight loss.
Need a deeper look?
The citation index lists every paper feeding this comparison. The safety matrix gives you the side-effect profile for each.
